BC Extra | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
BC Week In Review | Nov 16, 2018
Clinical News

Seal Rock's ASK1 inhibitor improves NASH symptoms in mice

Seal Rock Therapeutics Inc. (Seattle, Wash.) said lead candidate SRT-015 significantly improved metabolic parameters and liver-specific pathology in a mouse model of non-alcoholic steatohepatitis (NASH). The liver-selective apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) inhibitor also...
BC Extra | Sep 6, 2018
Company News

Management tracks: Rheos, Aileron

Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head of neuroscience, ophthalmology and rare disease for the Pharma Research and Early Development (pRED) group at Roche...
BC Week In Review | Jun 8, 2018
Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million on June 6 in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and...
BC Extra | Jun 6, 2018
Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and Vivo Capital also...
BioCentury | Dec 8, 2017
Finance

Negotiating NASH

New Enterprise Associates has signed onto Metacrine Inc.’s proposition that there is room to improve upon more advanced FXR agonists in development for non-alcoholic steatohepatitis. Metacrine closed an untranched $22 million series B round led...
BC Extra | Dec 7, 2017
Financial News

Metacrine raises $22M series B

Chronic disease company Metacrine Inc. (San Diego, Calif.) raised $22 million in a series B round led by new investor New Enterprise Associates. Existing investors Arch Venture Partners, Polaris, venBio and Alexandria Venture Investments also...
BC Week In Review | Sep 1, 2017
Financial News

Longevity closes second fund at $22M

Longevity Fund (Palo Alto, Calif.) closed its second fund at $22 million. The firm's Laura Deming told BioCentury that it plans to invest in eight to 10 companies, with investments focused on companies with "the...
BC Extra | Aug 23, 2017
Financial News

Longevity closes second fund at $22M

Longevity Fund closed its second fund at $22 million. The firm's Laura Deming told BioCentury that it plans to invest in eight to 10 companies, with investments focused on companies with "the potential to impact...
BC Week In Review | Aug 18, 2017
Company News

Metacrine partners with Novo Nordisk to develop FGF1 variants

Metacrine Inc. (San Diego, Calif.) partnered with Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to develop fibroblast growth factor 1 (FGF1) variants for glucose lowering and insulin sensitization. Metacrine said it has developed a large library of...
Items per page:
1 - 10 of 19
BC Extra | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
BC Week In Review | Nov 16, 2018
Clinical News

Seal Rock's ASK1 inhibitor improves NASH symptoms in mice

Seal Rock Therapeutics Inc. (Seattle, Wash.) said lead candidate SRT-015 significantly improved metabolic parameters and liver-specific pathology in a mouse model of non-alcoholic steatohepatitis (NASH). The liver-selective apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) inhibitor also...
BC Extra | Sep 6, 2018
Company News

Management tracks: Rheos, Aileron

Immunometabolism company Rheos Medicines Inc. (Cambridge, Mass.) hired Sanjay Keswani as CEO. He was SVP and global head of neuroscience, ophthalmology and rare disease for the Pharma Research and Early Development (pRED) group at Roche...
BC Week In Review | Jun 8, 2018
Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million on June 6 in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and...
BC Extra | Jun 6, 2018
Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and Vivo Capital also...
BioCentury | Dec 8, 2017
Finance

Negotiating NASH

New Enterprise Associates has signed onto Metacrine Inc.’s proposition that there is room to improve upon more advanced FXR agonists in development for non-alcoholic steatohepatitis. Metacrine closed an untranched $22 million series B round led...
BC Extra | Dec 7, 2017
Financial News

Metacrine raises $22M series B

Chronic disease company Metacrine Inc. (San Diego, Calif.) raised $22 million in a series B round led by new investor New Enterprise Associates. Existing investors Arch Venture Partners, Polaris, venBio and Alexandria Venture Investments also...
BC Week In Review | Sep 1, 2017
Financial News

Longevity closes second fund at $22M

Longevity Fund (Palo Alto, Calif.) closed its second fund at $22 million. The firm's Laura Deming told BioCentury that it plans to invest in eight to 10 companies, with investments focused on companies with "the...
BC Extra | Aug 23, 2017
Financial News

Longevity closes second fund at $22M

Longevity Fund closed its second fund at $22 million. The firm's Laura Deming told BioCentury that it plans to invest in eight to 10 companies, with investments focused on companies with "the potential to impact...
BC Week In Review | Aug 18, 2017
Company News

Metacrine partners with Novo Nordisk to develop FGF1 variants

Metacrine Inc. (San Diego, Calif.) partnered with Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to develop fibroblast growth factor 1 (FGF1) variants for glucose lowering and insulin sensitization. Metacrine said it has developed a large library of...
Items per page:
1 - 10 of 19